VMD Published Standards 2025 to 2026: Monitoring Performance
The UK Veterinary Medicines Directorate (VMD) published its official statistics report monitoring performance against published standards for the period 2025 to 2026 up to 31 March 2026. The report includes monthly performance summaries from September 2025 through March 2026. This is an informational publication providing performance data rather than establishing new regulatory requirements.
How MAHs Report Veterinary Medicine Defects
The UK Veterinary Medicines Directorate (VMD) has published guidance for Marketing Authorisation Holders (MAHs) on reporting product defects in veterinary medicines. MAHs must submit a completed Product defect report form to rapidalert@vmd.gov.uk and contact VMD to discuss recalls where a product or batch is likely to be recalled. The guidance also includes a table of recalled products from the last 12 months including recent recalls of Scabigard (April 2026), Hibiwash (March 2026), and Folltropin (November 2025).
Scabigard Suspension Class II Recall - Product Defect Affecting Efficacy
The UK Veterinary Medicines Directorate (VMD) has issued a Class II recall alert for Scabigard Suspension for Cutaneous Administration (Vm 42058/5173 and Vm 60021/3020) manufactured by Zoetis. The affected batches may fail to demonstrate expected signs of 'take' following administration. Nine batch numbers are affected, manufactured between June 2024 and January 2025, with expiry dates through December 2026. Wholesalers and veterinarians are required to immediately review inventory and quarantine affected products.
Top Ten Imported Veterinary Medicines Quarterly Report Q1 2026
The UK Veterinary Medicines Directorate published its quarterly statistical report on certificates issued under the Special Import System for Q1 2026. Artuvetrin Therapy led with 3,256 certificates (27% of total), followed by Arthramid Vet with 1,346 certificates (11%). The top ten products collectively account for 58% of all certificates issued during the period. This is an informational report with no regulatory obligations or compliance requirements.
Illegal Animal Medicines Seizures, Improvement Notices and Prosecutions
The Veterinary Medicines Directorate (VMD) publishes a rolling 12-month listing of enforcement actions under the Veterinary Medicines Regulations 2013 (VMR), including seizure notices, improvement notices, and prosecutions involving illegal animal medicines. The listing covers activities from August 2024 through April 2026, with updates added as enforcement actions occur. The VMD exercises powers of entry and inspector powers under the VMR to address non-compliance with animal medicine regulations.
Renewed Women's Health Strategy Published by DHSC and NHS England
DHSC and NHS England have published the renewed Women's Health Strategy, announcing plans to improve women's healthcare experiences across England. Key initiatives include a trial linking women's feedback to provider funding, a single referral point to reduce waiting lists for conditions like endometriosis, and new standards for pain relief during gynaecological procedures. The strategy aims to address systemic issues where women's symptoms have been dismissed or inadequately treated.
Donna Ockenden Appointed Chair of Independent Sussex Maternity Review
The UK Department of Health and Social Care has announced the appointment of Donna Ockenden as Chair of an independent review into Sussex maternity and neonatal services. Ockenden, known for leading the Shrewsbury and Telford NHS Trust review, was confirmed following direct engagement between the Health Secretary and bereaved families who campaigned for an independent review. The review is part of a government initiative to improve maternity safety across the NHS.
Clinical Trial Setup Time Falls to 122 Days
DHSC announces that average setup time for commercial interventional clinical trials in the UK has fallen to 122 days, down from 169 days for the same period last year. The £137 million investment in health research reforms has streamlined processes and reduced bureaucracy. This progress advances the Prime Minister's commitment to get UK clinical trials up and running within 150 days by March 2026.
Renewed Women's Health Strategy for England
The DHSC has published the Renewed Women's Health Strategy for England, a 10-year plan outlining how the government will improve women's health and healthcare. The strategy aligns with the 10 Year Health Plan for England and aims to ensure women have voice, choice and power in their health and healthcare. The strategy was published on 15 April 2026.
MHRA Annual Accountability Review Minutes 2015 to 2025
The Department of Health and Social Care has published transparency data listing MHRA annual accountability review minutes from 2014-15 through 2024-25. The page was updated on 15 April 2026 to add the 2024-25 review minutes from 29 October 2025. No new compliance obligations are created by this administrative listing.
Part 2A Health Protection Orders Transparency Data 2017-2025
UKHSA published anonymised transparency data summaries of statutory Part 2A health protection orders for financial years 2017-2018 through 2024-2025. Part 2A orders are statutory instruments used to protect public health through measures such as restricting movement, detaining individuals, and closing premises. The transparency data includes ODS format spreadsheet files for each financial year. No new compliance obligations are created for external parties.
Diphtheria Cases Among Asylum Seekers England 2022 to 2026
UKHSA publishes statistical data tables showing confirmed toxigenic Corynebacterium diphtheriae cases among asylum seekers in England from 2022 to 2026. The publication is updated quarterly, with the most recent update adding January to March 2026 data. The next scheduled update is 2 July 2026.
NOIDs Causative Agents: Weekly Reports for 2026
UKHSA publishes weekly lab reports on notifiable diseases and causative agents for 2026. The data covers weeks 1 through 15 (January through April 2026) with separate HTML reports for each week. The list of reportable organisms has been expanded to include additional notifiable organisms under updated requirements. Affected parties should monitor these weekly publications as the reporting requirements may have been updated to include new organisms that laboratories must notify UKHSA about.
HIV Annual Data 2025: Testing, PrEP, New Diagnoses and Care Outcomes
UKHSA published annual HIV surveillance data for 2025 covering HIV testing, PrEP, PEP, new diagnoses, AIDS, deaths, and care outcomes across England, Wales, Northern Ireland, and Scotland. Data tables include demographic breakdowns, geographic region analysis, and key population statistics from 2015 to 2024. A slide set for presentational use is also available.
HIV and AIDS Reporting System: NHS Quarterly Data Collection Guidance
The UK Health Security Agency (UKHSA) updated its guidance on HIV surveillance systems, describing three reporting mechanisms: HARS (quarterly disaggregate data from NHS-funded HIV outpatient providers in England), HANDD (new diagnoses and deaths from laboratories and sexual health services), and CHARS (clinical data on children with HIV). Data from Scotland, Northern Ireland, and Wales is submitted annually and linked to create a UK-wide HIV database.
Emend 125mg Shortage, Alternative Treatments Proposed
ANSM published guidance on April 15, 2026 regarding the shortage of Emend 125mg (aprepitant) oral suspension manufactured by MSD. The drug, used in chemotherapy for children and infants aged 6 months to under 12 years, became unavailable at the end of March 2026 due to production problems. ANSM has arranged alternative supplies including Ivemend 150mg imports and authorized pharmacists to dispense magistral preparations without new prescriptions.
Mektovi (Binimetinib) 15mg and 45mg Dosage Confusion Safety Alert
ANSM issued a drug safety alert regarding Mektovi (binimetinib), an anticancer medication, following 7 reported medication errors from confusion between the 15mg and 45mg tablet dosages. The errors, which began after the 45mg dosage became available in July 2025, resulted in overdoses causing hepatocyte cytolysis, intense fatigue, nausea, serous retinal detachment, and elevated lipase levels. The recommended dose is 90mg/day (either 3 tablets of 15mg or 1 tablet of 45mg twice daily).
Benefits Brief: Responding to a HIPAA Breach of 25 Million Individuals - Conduent Incident
Vorys, Sater, Seymour and Pease LLP published guidance on the Conduent Business Services cybersecurity breach affecting approximately 25 million individuals, including over 15.4 million Texas residents, between October 21, 2024 and January 13, 2025. The article analyzes HIPAA obligations for covered entities and business associates when a third-party vendor experiences a breach of protected health information.
'We're Open for Business': OCR Enforcing Part 2 SUD Records; NPP Updates Required
The HHS Office for Civil Rights (OCR) has assumed enforcement authority over 42 CFR Part 2 (confidentiality of substance use disorder records) from the Department of Justice, effective Feb. 16, 2026. OCR Director Paula Stannard stated the agency is 'open for business' for Part 2 violations. Both covered entities (CEs) and Part 2 providers were required to update privacy notices by the compliance date, with Part 2 providers adopting HIPAA-like standards and CEs updating their Notice of Privacy Practices (NPPs) to address Part 2 records.
340B Drug Pricing Litigation Update Covers 50+ Cases
McDermott Plus published a weekly roundup of 340B drug pricing litigation covering more than 50 cases in federal and state courts for April 7–13, 2026. Key developments include the Fifth Circuit affirming denial of preliminary injunctions in Mississippi contract pharmacy cases, the Sixth Circuit staying a Tennessee case pending similar proceedings, a new drug manufacturer complaint challenging government audit enforcement and patient-definition determinations, and a trade association filing challenging a Washington state contract pharmacy law.
BDSI Loses Motion to Enforce Belbuca Injunction
The U.S. District Court for the District of Delaware denied BioDelivery Sciences International's July 2025 motion to enforce a 2022 final judgment and injunction against Alvogen regarding generic Belbuca (buprenorphine buccal film). The court found that Alvogen's new ANDA product was a reformulation with a more basic backing layer pH than the original ANDA product, and therefore not substantially identical to the enjoined product.
CMS Targets Hospice Providers With Prepayment Reviews in Six States
CMS Medicare Administrative Contractors have been conducting expanded prepayment reviews (EPRs) of existing hospice providers since September 2024 in Arizona, California, Nevada, and Texas. As of December 2025, hospices in Georgia and Ohio have also been added to the review program. Husch Blackwell attorneys discuss how hospices can differentiate EPRs from other audit types, what to expect throughout the process, and strategies to overcome claim denials.
CMS FY 2027 IPPS Proposed Rule: 2.4% Payment Increase
CMS issued the FY 2027 IPPS proposed rule on April 10, 2026, proposing a 2.4% increase in operating payment rates for general acute care hospitals participating in the Hospital Inpatient Quality Reporting Program and meaningful EHR users, reflecting a 3.2% market basket increase less a 0.8% productivity adjustment. The proposed rule would nationalize the Comprehensive Care for Joint Replacement Model, require hospitals billing Medicare Part A and Part B to use CJR-X or TEAM for joint replacement episodes, eliminate the breakthrough device designation alternate pathway for new technology add-on payments, and make various MS-DRG changes.
Congressional Investigations Quarterly: Healthcare Affordability, Drug Prices, Insurance in Q1 2026
Morrison & Foerster LLP published its Congressional Investigations Quarterly covering Q1 2026. The report examines congressional investigations into healthcare affordability, focusing on health insurance company CEO testimony on premium costs, pharmacy benefit manager (PBM) practices and prescription drug pricing, the 340B Drug Pricing Program, and vision care market consolidation. Additional investigations cover algorithmic pricing by technology platforms and college tuition pricing.
FDA Approves Extended EYLEA HD Dosing Interval for Wet AMD and DME
The FDA approved an extension of the maximum dosing interval for Regeneron's EYLEA HD (aflibercept) from 16 weeks to 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The approval is based on 96-week data from the PULSAR and PHOTON pivotal trials, which demonstrated that the majority of patients maintained visual and anatomic improvements with extended dosing intervals. The new regimen allows patients to be treated as infrequently as 2 to 3 times per year.
CMS LEAD ACO 10-Year Program Launching Jan 2027
CMS is launching the Long-term Enhanced ACO Design (LEAD) Model on January 1, 2027, replacing the ACO REACH Model. The 10-year voluntary program (2027-2036) offers two risk tracks: Global Risk Option (100% shared savings/losses with 1.75-3% benchmark discount) and Professional Risk Option (50% shared savings/losses). New payment flexibilities include capitated payments, advanced monthly payments, and a Non-Primary Care Capitation mechanism enabling specialist sub-capitation.
FCA Recoveries, HHS Cuts, OCR Investigations in Healthcare
Spilman Thomas & Battle's healthcare law newsletter covers record False Claims Act recoveries of $6.8 billion in fiscal year 2025, proposed HHS budget cuts, HHS Office for Civil Rights investigations of 13 states, Virginia medical malpractice developments, North Carolina hospital fee scrutiny, hospital bad debt increases, and FDA warnings to telehealth companies regarding GLP-1 product claims. The newsletter also reviews West Virginia legislative impacts on healthcare.
Missouri Expands Verified Dispensary Initiative with Billboards Radio Advertising
The Missouri Department of Health and Senior Services announced an expansion of its Verified Dispensary public outreach initiative, adding highway billboards at 218 locations and radio advertisements on 85 stations reaching approximately 1.5 million residents with over 5 million impressions. The campaign provides tools to help Missourians identify state-licensed cannabis dispensaries and includes an updated dispensary locator map.
Oregon City Measles Exposure Location at Legacy GoHealth
Oregon Health Authority and Clackamas County public health officials identified a measles exposure location at Legacy GoHealth in Oregon City. Individuals present at the clinic between 9:09 a.m. and 12:22 p.m. on April 10, 2026, or between 1:12 p.m. and 3:48 p.m. on April 11, 2026, should contact their healthcare provider. OHA warns against relying on news outlets for exposure information and directs the public to its official measles website for accurate listings.
Centennial Middle School Measles Exposure Date Added
Oregon Health Authority and Multnomah County public health officials have added an additional measles exposure date to Centennial Middle School in southeast Portland. The new exposure period is April 3, 2026, between 9:20 a.m. and 6 p.m. The complete exposure list includes April 1, 3, 6, 7, 8, 9, and 10. Officials urge anyone present during these times to contact their healthcare provider to determine measles immunity status.
Syphilis Rates Drop 18.6%, Congenital Syphilis Down 32.4% in New Mexico
The New Mexico Department of Health announced declines in sexually transmitted infection rates for 2025 compared to 2024. Syphilis rates dropped 18.6%, congenital syphilis fell 32.4%, chlamydia dropped 5.1%, and gonorrhea dropped 6.1%. NMDOH attributes the declines to expanded community outreach, increased testing and treatment, promotion of Doxy PEP post-exposure prevention medication, and partnerships with community, medical, and Tribal organizations.
Cyanobacteria Advisory Lifted at Scott Pond
The Rhode Island Department of Health has lifted the cyanobacteria advisory at Scott Pond. The advisory, which warned the public to avoid contact with the water due to potential harmful algal blooms, has been removed following testing that indicated cyanobacteria levels have returned to safe conditions.
Aerys Medical Bed Half-Rails Safety Recall by Winncare France
ANSM has published a safety alert regarding a field safety corrective action (FSCA No. R2610462) conducted by Winncare France for Aerys and Aerys Confort sliding medical bed half-rails. Users of the affected products have received direct correspondence from Winncare France. The alert is directed to pharmacies, community care facilities, retail establishments, and home health service providers.
Scientific Literature Reference - Content Restricted
FDA received a submission on regulations.gov containing a scientific literature reference that is restricted due to copyright limitations. The specific content of the referenced literature is not accessible. The submission appears in FDA's docket system but the substantive regulatory material cannot be reviewed.
FDA Complaint FDA-2026-H-3943-0001
FDA received a complaint under docket FDA-2026-H-3943-0001 on April 15, 2025. The Center for Tobacco Products authored the complaint. The public comment period for this docket is now closed. No documents are available for viewing or download from the regulatory docket.
Citizen Petition to FDA by Kaylin Bower
A citizen petition was filed with the FDA's Center for Drug Evaluation and Research (CDER) by Kaylin Bower on April 15, 2026. The petition docket is FDA-2026-P-4104-0001. The full contents of the petition are redacted due to personally identifiable information protections, limiting visibility into the specific regulatory relief requested.
Scientific Literature Reference Copyright Restricted
FDA published a document on regulations.gov (FDA-2026-P-3869-0004) regarding scientific literature references. The submission contains copyright-restricted content and is not fully accessible to the public. The document appears to be a regulatory submission or comment filed with FDA.
Manhart 2013 Scientific Literature Submission FDA-2026-P-3869
FDA has received a docket submission to FDA-2026-P-3869 containing a citation to Manhart 2013 scientific literature. The full content of the submission is restricted due to copyright and is not publicly viewable in the docket.
Narula 2022 IBD Scientific Literature, FDA-2026-P-3869
Narula 2022 IBD Scientific Literature, FDA-2026-P-3869
Scientific Literature Reference Rao 2017 FDA-2026-P-3869
A scientific literature reference (Rao 2017) has been submitted to FDA docket FDA-2026-P-3869. The document appears to be supporting scientific literature provided as part of comments or a submission to the FDA regulatory process. No regulatory requirements, deadlines, or penalties are established by this document submission.
Scientific Reference Costenbader 2007, FDA-2026-P-3869
FDA has published a scientific reference document (Costenbader 2007) as part of docket FDA-2026-P-3869. The document was submitted as supporting scientific literature for a Pre-Market Notification submission. The actual content is restricted due to copyright and cannot be displayed.
Sanchez-Guerrero 1997 Scientific Literature Reference
FDA has received and filed a scientific literature reference (Sanchez-Guerrero 1997) in regulatory docket FDA-2026-P-3869. The document has been uploaded to the public docket and is accessible to interested parties. The content of the reference cannot be displayed due to copyright restrictions.
Yang 2022 Scientific Literature Reference
A scientific literature reference authored by Yang (2022) was submitted to FDA docket FDA-2026-P-3869 as supporting documentation. The document was filed on April 3, 2025, and is accessible via regulations.gov. This appears to be part of a food additive petition or similar regulatory submission process requiring scientific literature support.
Measles Case Identified in Weld County Resident
The Colorado Department of Public Health and Environment and Weld County Public Health have identified a measles case in an unvaccinated adult Weld County resident who is a close contact of previous cases. Potential exposure locations have been identified at two healthcare facilities in Larimer County. Public health officials are advising anyone who visited the listed locations at the specified times to monitor for symptoms for 21 days.
FDA Public Meeting on Dietary Supplement Ingredients
FDA's Office of Dietary Supplement Programs held a public meeting on March 27, 2026, to discuss the evolving landscape of dietary supplement ingredients and how scientific and technological advances are shaping the industry. The meeting covered three sessions: the scope of 'dietary supplements' under DSHEA, emerging production technologies, and identification of proteins, enzymes, and microbials. FDA posed three feedback questions to stakeholders regarding novel ingredient types, production methodology changes, and characterization requirements.
Texas Home Health Providers - HHSC-OIG Common Billing Errors and $95.7M Recovered
The Texas Health and Human Services Office of Inspector General (HHSC-OIG) recovered more than $95.7 million from December 1, 2025, to February 28, 2026. Home health agencies ranked first among provider types in preliminary investigations at 21 percent of cases and third in full-scale investigations at 15 percent. Common billing errors identified include failure to perform required nursing assessments, documentation deficiencies, and billing irregularities such as billing for services when clients were at inpatient facilities or misrepresenting nurse credentials.
Healthcare Incentive Decisions Resurface in Audits and Diligence
This article examines how healthcare incentive compensation decisions resurface during audits, partner disputes, payer challenges, and transaction due diligence. It identifies documentation patterns that create risk for healthcare organizations, including discretionary payments without adequate records, one-off compensation adjustments that become permanent without review, and inconsistent explanations for incentive payments. The article advises that when documentation is thin or inconsistent, reviewers fill gaps with risk assumptions.
A&O Shearman Releases Second Life Sciences and Healthcare Insights Report
A&O Shearman has released the second edition of its Life Sciences and Healthcare Insights report. The publication covers six topics including shareholder activism trends, AI use in drug discovery, China's emergence as a pharma innovation hub, proposed EU MDR and IVDR reforms, the UPC's impact on European patent litigation, and EU environmental sustainability requirements for pharmaceutical companies. The report is informational and does not create compliance obligations.
Recent Court Decisions Favor Employers in Tobacco Surcharge Litigation
Warner Norcross + Judd summarizes three recent federal district court decisions (Plesha v. Ascension Health Alliance, E.D. Mo.; Greene v. Progressive Corp., N.D. Ohio; Noel v. PepsiCo, Inc., S.D.N.Y.) dismissing ERISA class action claims challenging employer tobacco surcharge wellness programs. Courts held that employers need not provide retroactive refunds of tobacco surcharges, that disclosure language substantially similar to DOL model notice satisfies requirements, and that tobacco surcharge design is a settlor function rather than a fiduciary duty. The analysis signals a trend generally favorable to employers while noting dozens of similar lawsuits remain pending nationwide.
Healthcare Providers Warned About Medical Tech Contract AI, Evergreen Risks
Buchalter published an advisory warning healthcare providers about two emerging contract risks: (1) evergreen renewal provisions that automatically extend agreements without opportunity to renegotiate AI-related terms, and (2) expansive vendor data rights that may permit use of provider data for AI model training and product development without clear disclosure. The advisory identifies risks including re-identification of de-identified data, vendor IP accrual from provider operations, and unclear liability for AI-generated clinical or billing outputs.
California Senior Living–2026 Legal, Regulatory, and Insurance Update Webinar
Hinshaw & Culbertson LLP announces a webinar on April 29, 2026 for California senior living providers covering insurance market changes, claims trends affecting nursing homes and RCFEs, and legal developments influencing liability exposure. The webinar offers 1.0 hours of NAB and RCFE continuing education credits. This is an educational announcement with no regulatory changes or compliance mandates.
State Health Planning Board Confirms Public Hearing for Hospital Closure Certificate of Need Application
The New Jersey Department of Health's State Health Planning Board has scheduled a public hearing for April 15, 2026, to accept public comments on a Certificate of Need application for the closure of Heights University Hospital in Jersey City. The hospital application and related materials are available at the Jersey City Public Library, New Jersey State Library, and the NJDOH website. Written comments may also be submitted until April 22, 2026, via email or mail.
Roche Oligonucleotides for Paternal UBE3A Expression
The European Patent Office published patent application EP3798307A1 for F. Hoffmann-La Roche AG covering oligonucleotides designed to induce paternal UBE3A expression. The invention relates to nucleic acid therapeutics targeting UBE3A gene expression, with applications in treating genetic disorders. The patent application was filed under IPC classification C12N 15/113 and designates all 39 contracting states across the European Patent Convention.
Georgia SB 220 THC Cap, 12,000mg Limit, SB 33 Hemp
Two Georgia Senate bills await Governor Brian Kemp's decision by mid-May 2026. Senate Bill 220 would eliminate Georgia's 5% THC concentration cap and replace it with a 12,000-milligram patient possession limit, while rebranding 'Low THC Oil' to 'Medical Cannabis' throughout state code. Senate Bill 33 would ban synthetic hemp products like HHC by 2027 while preserving delta-8 THC products on the market.
Federal Court Vacates HRSA 340B GPO Prohibition Replenishment Model Policy
The US District Court for the District of Columbia vacated HRSA's 2013 policy prohibiting 340B covered entities from using group purchasing organizations with replenishment (virtual inventory) models. The court granted Premier's motion for summary judgment, finding HRSA's policy arbitrary and capricious under the Administrative Procedure Act due to inadequate reasoned explanation. The court denied defendants' cross-motion for summary judgment.
CAA 2026 Medicare Part D Pharmacy Provisions Primer
H.R.7148, the Consolidated Appropriations Act, 2026, became law on February 3, 2025, introducing new pharmacy-related requirements under Sections 6223 and 6224 focused on Medicare Part D. Section 6223 expands 'Any Willing Pharmacy' contracting requirements and creates new affiliate and non-affiliate pharmacy designations, while Section 6224 limits PBM compensation to bona fide service fees and requires passthrough of manufacturer rebates and discounts to PDP sponsors.
Life Sciences and Healthcare Insights (UPDATED)
A&O Shearman published its Life Sciences and Healthcare Insights report, offering a global compilation of legal and regulatory updates from the firm's international team. The report addresses commercial, legal, and regulatory issues affecting life sciences and healthcare companies worldwide. Topics covered include environmental sustainability, regulatory frameworks, and emerging compliance considerations across jurisdictions.
FDA Clarifies GLP-1 Compounding Policy for Pharmacy Compounders
FDA Clarifies GLP-1 Compounding Policy for Pharmacy Compounders
HIPAA PHI Disposal Requirements, Methods, and Training
Shumaker, Loop & Kendrick published a client alert summarizing HHS guidance on HIPAA Privacy and Security Rule requirements for disposing of protected health information. The alert explains that covered entities must implement reasonable safeguards, policies, and procedures for PHI disposal in any form, and must train workforce members on disposal practices. The article references 45 CFR 164.530(c) and 45 CFR 164.310(d)(2)(i) and (ii).
Percussionaire Corp Issues Phasitron 5 In-Line Valve Correction, Updates Use Instructions
Percussionaire Corporation issued an Urgent Medical Device Correction for the Phasitron 5 In-Line Valve (P5-TEE) due to a design limitation where leaks can occur through the pressure relief valve even when fully closed. The FDA classified this as a Class I recall, the most serious type. Leakage poses a high risk of cardiopulmonary and neurological compromise in neonatal and infant patients due to unrecognized hypoventilation, potentially causing respiratory acidosis, hypoxemia, or respiratory failure. Four serious injuries have been reported as of September 3, 2025, with no deaths.
Larsen 2008 FDA Document
This document (FDA-2026-P-3869-0117) appears in the FDA section of Regulations.gov. The full content is not accessible as it has been restricted due to copyright protections. No substantive regulatory requirements, deadlines, or obligations can be determined from the available metadata.
Chen 2017 Background Material, FDA-2026-P-3869, Apr 3
Chen 2017 Background Material, FDA-2026-P-3869, Apr 3
Persson 1993 Background Material, FDA-2026-P-3869
FDA has posted background material submitted by Persson in docket FDA-2026-P-3869. The document, dated 1993, has been added to the public docket. The content is restricted due to copyright. No specific regulatory requirements or deadlines are stated in the available metadata.
Piovani 2019 Supplemental Tables Supporting FDA Petition
FDA received supplemental tables (Piovani 2019) as supporting material filed under docket FDA-2026-P-3869. The document contains scientific data tables submitted to support a petition or submission before the agency. Affected parties should monitor this docket for related FDA actions or correspondence.
Hellwig 2016 Background Material - FDA Docket FDA-2026-P-3869
FDA received background material originally prepared in 2016 and filed in docket FDA-2026-P-3869. The document appears to be supporting documentation associated with an FDA petition. No new regulatory requirements or compliance obligations are established by this filing.
Persson 1993 Background Material Submission FDA Docket
FDA has received and placed in docket FDA-2026-P-3869 background material titled 'Persson 1993' for public access. The document contains copyrighted content that is restricted from public viewing. This appears to be historical scientific literature submitted as supporting material in an FDA regulatory proceeding. No new regulatory requirements, deadlines, or compliance obligations are established by this docket filing.
Klaus 1982 FDA Document
FDA received a document submission dated April 15, 1982, from Klaus. The document content is restricted due to copyright and is not publicly accessible through regulations.gov. The submission is catalogued under docket FDA-2026-P-3869-0005. Specific regulatory content cannot be determined from the available metadata.
Peragallo 2018 Supporting Material FDA-2026-P-3869
FDA received supporting materials for Citizen Petition FDA-2026-P-3869 submitted by Peragallo. The document consists of 2018 supporting material referenced in the petition but the content is restricted due to copyright. The petition and supporting documentation were filed in the public docket for regulatory review.
Ghajarzadeh 2022 Background Material for FDA Petition
FDA received background material from Ghajarzadeh dated 2022 as part of petition FDA-2026-P-3869. The submission consists of supporting documentation for a petition requesting FDA to take a specific regulatory action. The document was filed in the FDA regulations.gov docket system. No specific petition request, compliance obligations, or deadlines are stated in the available metadata.
Raglan 2019 Supporting Material
FDA received supporting material dated April 15, 2019, associated with submission FDA-2026-P-3869. The document content is restricted due to copyright. No specific regulatory requirements, deadlines, or penalties are stated in the visible portion of the document.
Konkle 2012 Background Material - FDA-2026-P-3869
FDA has received and posted background material (Konkle 2012) as part of docket FDA-2026-P-3869. The document content is restricted due to copyright and is not publicly accessible. The filing represents supporting documentation submitted to the FDA docket for regulatory review.
FDA READI-Home Innovation Challenge for Medical Device Technologies
The FDA's Center for Devices and Radiological Health (CDRH) launched the Reducing Readmissions through Device Innovation for the Home (READI-Home) Innovation Challenge on April 7, 2026. The challenge invites medical device innovators to develop home-based technologies that support patients and caregivers following acute hospital stays and help prevent readmissions. Submissions must meet the FD&C Act device definition and address unmet home healthcare needs.
Call for Nominations for Center for Indigenous Innovation and Health Tribal Advisory Committee
The HHS Office on Minority Health (OMH) is accepting nominations for primary and alternate delegates to serve on the Center for Indigenous Innovation and Health Tribal Advisory Committee (CIIH TAC). The CIIH TAC provides tribal leaders a forum to exchange views and provide feedback on activities addressing four priority areas: research, education, service, and policy development. Nomination letters must be submitted by May 18, 2026.
Advisory Council on Alzheimer's Research, Care, and Services Meeting
HHS announces a public meeting of the Advisory Council on Alzheimer's Research, Care, and Services scheduled for Monday, April 27, 2026, from 1:00 p.m. to 5:00 p.m. The meeting is open to the public for attendance and comment participation. This is a routine advisory council meeting announcement with no new compliance obligations.
CDC Proposes Data Collection Under Paperwork Reduction Act
CDC proposes a new data collection under the Paperwork Reduction Act and seeks public comments. The notice requests feedback on the proposed data collection, associated burden estimates, and collection methods. Comments are due June 15, 2026.
CDC Proposes Data Collection Under Paperwork Reduction Act
The CDC has published a notice proposing a new data collection under the Paperwork Reduction Act. The notice requests public comments on the proposed collection of information. The comment period closes 61 days from the date of publication.
CDC Agency Forms Undergo Paperwork Reduction Act Review
CDC published a notice announcing that certain agency forms are undergoing the Paperwork Reduction Act review process. The notice identifies forms under review by docket number 30Day-26-1335 and invites public comment on these information collections. Affected parties who submit information to CDC using these forms may wish to monitor the review for any changes to reporting requirements.
CMS Schedules June 2026 Public Meeting on HCPCS Level II Code Revisions
CMS announces the first biannual 2026 public meeting for HCPCS Level II coding to discuss preliminary coding, Medicare benefit category, and payment determinations for new non-drug and non-biological items and services. The primary meeting is scheduled for June 1, 2026, in Baltimore with a virtual overflow option on June 2, 2026. Speaker registration and in-person attendance requests are due by May 18, 2026, and written comments may be submitted until June 3, 2026.
FDA Oversight of Compounded GLP-1 Drugs, Active
HHS OIG announced an active study to assess FDA's oversight of compounded glucagon-like peptide-1 receptor agonist (GLP-1) drugs. The study will examine FDA's inspection of compounding facilities and use of available data to identify and address potential risks to patients. GLP-1 drugs were on FDA's drug shortage list from 2022 to 2025, during which compounding facilities were permitted to produce copies. The study is estimated for completion in fiscal year 2028.
NIH Recipients' Oversight of Domestic Subrecipients
HHS OIG announced a new evaluation (OEI-04-26-00170) to assess NIH prime recipients' adherence to requirements for oversight of domestic subrecipients under the NIH Grants Policy Statement and OMB Uniform Guidance. The evaluation aims to reduce fraud, waste, and abuse in domestic NIH subawards, with an estimated completion date of FY2028.
TANF Cash Assistance Program Oversight Audit Series Announced
HHS OIG announced a new audit series (SRS-A-26-017) to examine state oversight of the Temporary Assistance for Needy Families (TANF) program, which distributes $16.6 billion annually in federal block grant funds to states. The audits will focus on whether states provided adequate oversight of TANF cash assistance programs, including the use of electronic benefit transfer (EBT) cards. One project (OAS-26-09-021) has been announced with an estimated completion in FY2028.
IDOH Vital Records LHD Webinar
The Indiana Department of Health has scheduled a virtual webinar on vital records for Local Health Department staff on April 16, 2026 from 10:00am to 11:00am EDT. The event is hosted by IDOH's LHD Program and appears to be an informational training session. No regulatory requirements, compliance obligations, or new policies are being established through this event.
Delaware Healthy Mother & Infant Consortium Celebrates 20th Anniversary During Annual Summit
The Delaware Healthy Mother & Infant Consortium marked its 20th anniversary at its annual summit with a keynote address by Multi-Emmy Award-winning director Emmai Alaquiva. Alaquiva discussed his award-winning film The Ebony Canal and addressed maternal health disparities affecting Black and Brown communities. The event celebrated the consortium's two decades of work on infant outcomes in Delaware.
Cancer Vaccine Patent hESCs TLR3 Adjuvant Assigned to INSERM
USPTO granted patent US12599662B2 to INSERM for a cancer vaccine composition using irradiated human embryonic stem cells combined with a TLR3 adjuvant. The patent covers methods for treating cancers including breast cancer by inducing MHC-I presentation of antigens. The patent includes 16 claims.
USPTO Patent US12601742B2 for Endometrial Cancer Treatment Methods
USPTO granted patent US12601742B2 to Mayo Foundation for Medical Education and Research covering methods and materials for assessing and treating endometrial cancer. The patent covers methods for identifying endometrial cancers likely to respond to particular cancer treatments by assessing combinations of mutations and expression levels, such as platinum-based therapies. The patent contains 22 claims.
Sudan Crisis, 4M Malnourished, 37% Health Facilities Closed
WHO reports that three years of conflict in Sudan have created the world's largest humanitarian and displacement crisis. Nearly 4 million people are estimated to be acutely malnourished in 2026, with disease outbreaks including malaria, dengue, measles, and polio spreading across multiple states. Some 37% of health facilities across Sudan's 18 states remain non-functional, while WHO has verified 217 attacks on health care since April 2023.
Safety Assessment of Genome Editing Human Gene Therapy Products Using Next-Generation Sequencing
FDA's Center for Biologics Evaluation and Research has issued draft guidance recommending next-generation sequencing (NGS)-based methods for assessing safety of human genome editing gene therapy products in nonclinical studies. The guidance addresses evaluation of off-target editing risks and genome integrity for products supporting IND and BLA applications. Comments are being accepted via regulations.gov under docket FDA-2026-D-1255.
STI Awareness Week: Talk, Test, Treat
MSDH announces STI Awareness Week (April 12-18) and releases 2025 STI trend data. Reported changes include: 2.4% increase in chlamydia, 0.6% decrease in gonorrhea, 21.9% decrease in syphilis, 48% decrease in congenital syphilis, and 4.9% decrease in HIV. The department promotes Talk, Test, Treat messaging and provides information on free testing, PrEP, and condom distribution at county health clinics.
Tribal Consultation Meeting HHS/ACF OHS Head Start Programs
HHS/ACF OHS announces a Tribal Consultation session on June 18, 2026, to meet with tribal government leaders operating Head Start and Early Head Start programs. The consultation will address funding allocations, distribution formulas, and service delivery for American Indian and Alaska Native children and families. A report will be published within 45 days of the meeting.
Center for Scientific Review Notice of Closed Meetings
The NIH Center for Scientific Review announces five closed meetings scheduled for May 8, 2026. Review panels will evaluate grant applications in oncological sciences, medical informatics, genetics, endocrinology, and career development awards. Meetings are closed pursuant to the Federal Advisory Committee Act due to confidential grant information.
Center for Scientific Review Notice of Closed Meetings
The National Institutes of Health Center for Scientific Review announces five closed meetings scheduled for May 12-13, 2026. The meetings will review and evaluate grant applications for clinical vision research, reproductive/perinatal/pediatric health, contraceptive development, immunity/host defense, and aging tissue research. Meetings are closed under provisions of the Federal Advisory Committee Act because discussions could disclose confidential trade secrets, commercial property such as patentable material, and personal information of individuals associated with grant applications.
Financial Transparency and Efficiency of PDUFA, BsUFA, and GDUFA; Public Meeting
The FDA is announcing a public meeting on June 23, 2026, to discuss financial transparency and efficiency of the Prescription Drug User Fee Act (PDUFA), Biosimilar User Fee Act (BsUFA), and Generic Drug User Fee Amendments (GDUFA). The hybrid meeting will be held at FDA White Oak Campus and via Microsoft Teams. Written and electronic comments on the meeting topic must be submitted by July 23, 2026.
Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments
The FDA announced a public meeting on April 23, 2026 to gather stakeholder perspectives on increasing access to nonprescription drugs. The meeting will be held virtually and in person at the National Press Club in Washington, DC. Written and electronic comments are due by May 8, 2026.
Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry
FDA announced availability of draft guidance providing recommendations for next-generation sequencing (NGS)-based methods used in nonclinical studies to support initiation of clinical trials of investigational human genome editing products. The draft guidance is open for public comment until July 14, 2026 (90-day comment period). Comments should be submitted to Docket No. FDA-2026-D-1255.
Peptide Amide Composition for Kappa Opioid Receptor Treatment
USPTO granted Patent US12599647B2 to Xizang Haisco Pharmaceutical Co., Ltd. for a peptide amide composition containing a compound of formula (I) and pH regulators (pH 3-5.5). The composition is designed for treating or preventing diseases or conditions associated with kappa opioid receptors. The patent includes 19 claims and covers the compound composition, preparation methods, and medical applications.
Nestlé Granted Patent for Green Coffee Insulin Treatment Composition
USPTO granted Patent US12599643B2 to Societe des Produits Nestle S.A. for green coffee-based compositions comprising hydrolysed chlorogenic acid for improving insulin profile. The patent covers compositions for treating or preventing disorders linked to increased plasma postprandial insulin, including esterase treated decaffeinated green coffee extract with 40-200 mg daily dosage. The patent contains 16 claims and was filed March 27, 2020.
Free Soil Testing Events Hot Springs April 22-25
The Arkansas Department of Health announces free soilSHOP events in Hot Springs on April 22-25, 2026. Partnering with Master Gardeners of Garland County, Child Care Aware, National Park College, ATSDR, and EPA Region 6, the events will offer free lead screening of soil samples and health education on environmental hazards. Up to three soil samples per person may be submitted for testing.
Acellular Amniotic Fluid for Ischemic Injury Treatment
USPTO granted patent US12599635B2 to University of Utah Research Foundation covering compositions and methods for treating ischemic injuries using acellular amniotic fluid (acAF). The patent names inventors Hadi Javan, Craig H. Selzman, Young Sook Lee, Jo-Anna Reems, and Jan L. Pierce, and includes 31 claims. The patent application was filed March 22, 2021 under application number 17912730.
Thrombolytic Agents for Intravascular Clots - US12599653B2
The USPTO granted Patent US12599653B2 to Jinis Co., Ltd. for a thrombolytic agent comprising a dual-domain polypeptide with a thrombo-recognition domain and a thrombolytic domain effective for dissolving intravascular thrombus. The patent covers a pharmaceutical composition designed to prevent and treat thrombosis with reduced bleeding side effects compared to conventional thrombolytic therapies. The patent application was filed October 19, 2020, under Application No. 17770795.
CyPep-1 Peptide Composition for Treating Neoplastic Lesions
USPTO granted patent US12599646B2 to CYTOVATION ASA covering a pharmaceutical composition comprising therapeutic peptide CyPep-1 for treating neoplastic lesions, particularly warts. The patent, with 16 claims, was filed on March 10, 2020, and includes CPC classifications related to peptide formulations and therapeutic applications.
Cytotoxic Imidazopyridine Compounds and Their Use in Therapy
The USPTO granted Patent US12599676B2 to MyricX Pharma Limited for cytotoxic imidazo[1,2-A]pyridine compounds and their therapeutic use. The patent covers compounds of formula (I) classified under A61P 35/00 for cancer therapy. The application (19072750) was filed March 6, 2025, and the patent contains 23 claims.
Integrin α10-Selected MSCs Treat Skin Defects
USPTO granted patent US12599633B2 to Xintela AB covering integrin α10-selected mesenchymal stem cell compositions for treating skin defects, with 20 claims. The patent protects cell populations and culture conditions that enhance viability and regenerative function in wound healing applications.
US12599620B2 - Chronic Fatigue Syndrome Plasma Cell Inhibitor Treatment Method
The USPTO granted Patent US12599620B2 to Vestlandets Innovasjonsselskap AS covering a method for treating chronic fatigue syndrome using inhibitory or cytotoxic agents against plasma cells. The patent also claims combinations of plasma cell-targeting agents with B-cell depleting agents or B-cell activation inhibitors. The patent application was filed on August 31, 2020, under application number 17638453, and contains 3 claims.
Demethylating Agent Melanoma Treatment Method Using STING Signaling Enhancement
USPTO granted patent US12599621B2 to H. Lee Moffitt Cancer Center covering methods for enhancing anti-tumor T cell responses in melanoma subjects with defective STING signaling using demethylating agents. The patent, filed January 21, 2021, includes claims to methods of treatment involving demethylating agents, STING agonists, and tumor infiltrating lymphocytes. Inventors: James Mulé, Rana Falahat, Glen Barber.
SIRPγ Inhibitor for Cancer Treatment | US12599650B2
USPTO granted patent US12599650B2 to AMGEN INC. covering methods of treating tumors or cancer using SIRPγ inhibitors. The patent, invented by Ruozhen Hu, Paolo Manzanillo, and Wenjun Ouyang, contains 9 claims. Filing date was June 23, 2020 (Application No. 17618922).
MaxCyte Electroporation Device Design Patent USD1122471S1
The USPTO granted Design Patent USD1122471S1 to MaxCyte, Inc. for an electroporation device design. The patent application was filed on March 5, 2025, with inventors James William Luther, Bertold Engler, Andrea Besana, and Thomas Alan Peach. One design claim was granted. Design patents protect the ornamental appearance of a functional item for a term of 15 years from grant date.
Pharmaceuticals and Dosing Means for Human Aging Reversal
The USPTO granted patent US12599651B2 to Intervene Immune Inc. on April 14, 2026. The patent covers pharmaceutical compositions combining human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin for reversing age-related changes including systemic inflammation, cancer risk, thymus function, immune cell populations, and epigenetic age. The patent contains 11 claims.
EMS Training Committee to Meet Thursday, Apr. 16, 2026
The South Carolina Department of Public Health announces that the EMS Training Committee will meet on Thursday, April 16, 2026 at 10 a.m. at the State of South Carolina Health Campus, Conference Room A141, 400 Otarre Parkway, Cayce. The meeting is open to the public and the agenda and virtual viewing link are available on the meeting event page.
Kyprolis Visible Particles After Reconstitution - Safety Communication
Swissmedic issued a health professional communication regarding Kyprolis (carfilzomibum) 10 mg and 60 mg following routine stability monitoring that detected visible particles (transparent, colorless) in reconstituted samples. All distributed batches remain safe for use. The communication emphasizes strict adherence to visual inspection procedures per approved reconstitution instructions before administration.
Draeger Atlan A350 and A350 XL Anesthesia Workstation Correction
FDA classified Draeger Atlan A350 and A350 XL anesthesia workstations as a Class I recall—the most serious type—due to potential piston ventilator failure before or during use. Draeger is instructing customers to inspect and, if necessary, replace the ventilator motor assembly. Healthcare providers may continue using affected devices under permanent supervision until the corrective action is implemented.
Allosource Pelvic Organ Prolapse Implant Design Patent USD1122447S1
USPTO granted Allosource a design patent (USD1122447S1) for a pelvic organ prolapse implant. The patent was filed April 29, 2025, and granted April 14, 2026, with 1 claim. Inventors include McKenzie Pietrafeso, Charles Manuele, Madeleine Dahl, and Reginald Stilwell.
Posture Corrector Design Patent - Lei Pang, USD1122455S1
USPTO granted Design Patent USD1122455S1 to inventor Lei Pang for a posture corrector device. The design patent, with application number 29947562 filed June 17, 2024, covers the ornamental design of the posture corrector. The patent contains one claim and is classified under CPC codes A41D 1/00 and A61F 5/00 among others.
Talus Implant Design USD1122446S1, RESTOR3D
USPTO granted Design Patent USD1122446S1 to RESTOR3D, INC. for a Talus Implant design. The patent, with CPC classifications covering foot/ankle implants (A61F 2/42, A61F 2/66), was filed on May 10, 2023 under Application No. 29875805 and contains 1 design claim.
Standard Textile Incontinence Pad Patterned Surface
USPTO granted Design Patent USD1122441S1 to Standard Textile Co., Inc. for an incontinence pad with patterned surface design. The patent has 1 claim under application number 29877572 filed June 8, 2023. Competitors in the incontinence or hygiene product market should review this design patent for potential ornamental design overlap.
Window Handcrank Manipulator Design Patent USD1122478S1
USPTO granted design patent USD1122478S1 for a Window Handcrank Manipulator invented by Robert Fritz. The patent was issued April 14, 2026, with Application No. 29929345 filed February 21, 2024. The design patent contains 1 claim and covers a mechanical device design used for operating window cranks.
Rural Health FQHC Requirements, Certification, Services
CMS Medicare Learning Network published MLN006397, a booklet covering Federally Qualified Health Center (FQHC) requirements, certification standards, covered services, payment methodologies, and cost reporting obligations. The publication serves as an educational resource for current and prospective FQHCs.
US12599625B2 - Nitrous Oxide Oxygen Inhalation Therapy for ARDS
The USPTO granted Patent US12599625B2 to Penland Foundation on April 14, 2026, covering nitrous oxide and oxygen inhalation therapy for treating ARDS and conditions caused by elevated cytokine levels. The patent, invented by Roland M. Williams, contains 22 claims classified under A61K 33/00 and A61P 11/16. The treatment method involves administering nitrous oxide and oxygen by inhalation before, during, and/or after ARDS occurs to address acute cytokine system activation from infections, injuries, or other conditions.
Therapy Efficacy Method via Tissue Analysis, Arion Diagnostics
USPTO granted Patent US12599349B2 to Arion Diagnostics, Inc. covering a method for determining therapeutic agent efficacy through non-invasive biological tissue characterization. The method involves measuring molecular structure of tissue at two time points and observing changes to determine efficacy. The patent includes 27 claims and covers therapeutic applications across multiple CPC classifications including oncology, immunology, and neurological disorders.
Method of Obtaining Pharmaceutical Agent Inhibiting HeLa Cervical Cancer Cells
USPTO granted Patent US12599626B2 to LLC 'Laboratory of Innovative Technologies' on April 14, 2026. The patent covers a method for producing a pharmaceutical agent for inhibiting proliferation of HeLa cervical cancer cells using metal powder obtained via electric wire explosion of low-carbon steel. The invention involves exploding wire with specific energy of 7-18 KJ/g in carbon monoxide, followed by passivation, mixing with RPMI-1640 nutrient medium, and phase separation to produce the therapeutic agent.
US12599617B2 Methods of Treating Head and Neck Cancers with Hemp Extract Containing CBD
The USPTO granted Patent US12599617B2 to Dove Innovation Pty Limited covering methods of treating head and neck cancers using compositions containing hemp-derived CBD. The patent, with 17 claims, specifically covers mucosal formulations of cannabis extract for cancer treatment. Inventors include Alexandra M. Capano, Pradeep Singh Tanwar, and Alex Nance.
Salt Inducible Kinase Inhibitors Patent Granted to General Hospital Corporation
USPTO granted patent US12600719B2 to General Hospital Corporation covering salt inducible kinase (SIK) inhibitor compounds and pharmaceutical compositions. Inventors Marc Nathan Wein and William J. Greenlee filed the application on August 5, 2021. The patent contains 20 claims under CPC classification C07D 471/04.
Tricyclic KRAS Inhibitor Patent - Incyte Corporation
The USPTO granted Patent US12600717B2 to Incyte Corporation on April 14, 2026 for tricyclic compounds as inhibitors of KRAS activity. The patent contains 34 claims covering Formula I compounds useful in treating diseases associated with KRAS activity, including cancer. Filing date was July 13, 2022, under application number 17812310.
Washington University Patent for Toxoplasma Gondii Treatment Compounds
The USPTO granted Patent US12600727B2 to Washington University on April 14, 2026, covering compounds and methods for treating infections caused by Toxoplasma gondii and related parasites. The patent includes 18 claims and lists inventors L. David Sibley, Joshua Radke, Eamon Comer, Marshall Morningstar, and Bruno Melillo. This grant provides Washington University with exclusive intellectual property rights for the developed antiparasitic compounds and their pharmaceutical applications.
ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2
USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.
NURIX BTK Degrading Compounds, 36 Claims, Apr 14
The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.
Tetracyclic DGK Inhibitor Compounds for Cancer Treatment
USPTO granted Patent US12600722B2 to Incyte Corporation for tetracyclic compounds that modulate diacylglycerol kinase (DGK) activity, useful in treating cancer including solid tumors. The patent names Joshua Hummel, Shicheng Shi, and Xiaozhao Wang as inventors and contains 63 claims.
Nanjing University of Chinese Medicine - US12600724B2 Indole Alkaloid Compound and Preparation Method
The USPTO granted Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound represented by formula (I), including its preparation method and pharmaceutical salts. The compound has demonstrated therapeutic effects in animal studies, including promoting axon growth in peripheral sensory neurons, improving nerve conduction velocity in diabetic rats, accelerating foot ulcer wound healing, reducing pulmonary fibrosis, and protecting lung tissues. The patent contains 13 claims covering the compound, formulations, and methods of treatment for diabetic complications.
Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2
The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.
Interleukin-17 Inhibitors Patent - Novartis AG
The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.
ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant
The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.
Interoperability Standards for Prior Authorization APIs for Medicare Advantage, Medicaid, CHIP, and QHP Issuers
CMS proposes requiring Medicare Advantage organizations, Medicaid FFS programs, CHIP FFS programs, Medicaid managed care plans, CHIP managed care entities, and QHP issuers on FFEs to implement electronic prior authorization APIs for drugs. The rule would extend existing interoperability requirements to cover drug prior authorizations, adopt HL7 FHIR standards as HIPAA-covered transaction standards, require API endpoint reporting to CMS, and add a definition of failure to report for civil monetary penalty purposes.
Acknowledgment Letter to Mom3nts Production
FDA's Center for Devices and Radiological Health (CDRH), Division of Manufacturers and Communication (DMB), issued an acknowledgment letter to Mom3nts Production. The letter confirms receipt of a submission filed under docket FDA-2025-V-3791. No documents are available for public viewing on Regulations.gov; the letter content is contained in an attachment.
FDA Center for Tobacco Products Files Complaint - April 2026
The FDA Center for Tobacco Products (CTP) filed a complaint on April 14, 2026, initiating a formal enforcement action against tobacco product manufacturers. The complaint was submitted to regulations.gov under docket FDA-2026-H-3832. This filing represents FDA's regulatory enforcement mechanism for addressing violations of tobacco product standards under the Family Smoking Prevention and Tobacco Control Act.
FDA Center for Tobacco Products Complaint Submission
The FDA Center for Tobacco Products received a complaint document under docket FDA-2026-H-3868. The comment period has closed and no documents are available for public viewing. The nature and content of the complaint are not accessible through the regulatory filing system.
US12599785B2: Wearable Stereotactic Device, Apr 14
US12599785B2: Wearable Stereotactic Device, Apr 14
Medical Instrument with Consistent Smoothness of Action - US12599392B2
The USPTO granted Patent US12599392B2 to Aesculap AG for a medical instrument featuring improved pivot mechanism design with bearing portions and shoulder elements that ensure consistent sliding action. The patent, filed October 18, 2021, contains 19 claims covering surgical instruments with enhanced operational smoothness. Aesculap AG and its inventors Sven Barthelmes, Holger Loesdau, Christian Stark, and Markus Knecht hold the rights to this technology.
Electrode Balloon Catheter and High-Voltage Generation Processing Device Patent Grant
USPTO granted Patent US12599391B2 to Shanghai Microport Rotapace Medtech Co., Ltd. for an electrode balloon catheter and high-voltage generation processing device. The invention includes a balloon, inner catheter, and shock wave generation component with a flexible circuit layer enabling reduced passage size. The patent contains 15 claims and covers electrode arrangements positioned within the balloon connected via flexible circuitry.
US12599389B2 - Multi-Sided Cutting Instrument for Mobilizing Small Foot Bones
USPTO granted patent US12599389B2 to Treace Medical Concepts, Inc. covering a multi-sided orthopedic cutting instrument with multiple cutting surfaces designed for mobilizing and realigning small bones in the foot. The invention includes a handle and cutting head with lead and side cutting surfaces arranged to control soft tissue cutting while limiting inadvertent deep penetration. The patent contains 31 claims and is classified under CPC codes A61B 17/1682, A61B 17/32, A61B 17/1659, and A61B 17/1604.
Zimmer Patent for Bone Graft Delivery Systems Granted
The USPTO granted Patent US12599388B2 to Zimmer, Inc. covering bone graft delivery devices and methods. The invention includes a cannula and cartridge system for compacting and delivering bone material through fluid communication to an implantation site. The patent names six inventors and contains 15 claims.
Emergency Protocol Receptacle for Puncture Wounds - Patent US12599387B2
USPTO granted Patent US12599387B2 to Jesse Radford for an emergency protocol receptacle designed for puncture wounds. The invention utilizes an endothermic chemical reaction between vinegar and baking soda to inflate a balloon, facilitating faster blood coagulation in puncture-type wounds. The patent covers a balloon, powder capsule, and depressible top cap configuration.
LAA Occlusion Devices, Systems, and Methods Patent US12599386B2
USPTO granted patent US12599386B2 to Laminar, Inc. covering devices, systems, and methods for occluding the left atrial appendage (LAA) using implants that expand against cavity walls and twist to gather tissue, which can then be secured with fasteners. The patent, granted April 14, 2026, contains 5 claims and was filed August 28, 2020.
Olympus Endoscope System and Endoscopic Ligator Attachment Method Patent US12599385B2
The USPTO granted Patent US12599385B2 to Olympus Medical Systems Corp. for an endoscope system and endoscopic ligator attachment method. The patent covers an endoscope with an insertion section, a coupling thread with a coupling portion and thread portion, and a distal end cover that moves on the outer surface of the insertion section. The patent contains 18 claims and issues from Application No. 18115937, which was filed on March 1, 2023. This patent grant establishes enforceable intellectual property rights for Olympus Medical Systems Corp., granting them exclusive rights to practice the claimed endoscope system invention. Competitors in the medical device sector should monitor this patent when developing similar endoscopic devices to avoid potential infringement. The patent provides 20-year exclusivity from the filing date.
Bard Vascular Occlusion Device Patent US12599384B2 Granted
USPTO granted US Patent No. 12,599,384 (B2) to Bard Peripheral Vascular, Inc. on April 14, 2026, for a vascular occlusion device featuring an adjustable body with a pair of lobes and an adjustment assembly. The device allows modification of lobe distance through an elongated member and receiving member mechanism. The patent includes 20 claims and covers methods of use for vascular occlusion procedures.
FDA Form 483 Response Guidance, March 2026 Draft
FDA Form 483 Response Guidance, March 2026 Draft
Congress Returns, Healthcare Hearings, Kennedy Testifies
McDermott+ Consulting published a weekly healthcare preview noting Congress has returned from recess with a full agenda focused on DHS funding and potential reconciliation legislation. HHS Secretary Robert F. Kennedy Jr. is scheduled to testify before three House committees regarding the President's FY 2027 HHS budget priorities. Multiple healthcare-related committee hearings are scheduled, including sessions on chronic disease prevention, healthcare innovation, fraud prevention in state-run programs, and public health legislation.
China Pharma Innovators Pursue Global Expansion via Licensing Deals
A&O Shearman published analysis on how Chinese pharmaceutical companies are expanding internationally through out-licensing, partnership, and NewCo deal structures. The article examines China's emergence as a leading pharma innovation hub responsible for 29% of the world's innovative drug pipeline, with regulatory approval times reduced from 663 days in 2017 to 105 days in 2024. Key legal and regulatory angles for these transaction structures are discussed.
100% Section 232 Tariffs on Patented Drugs, APIs, and Key Materials
The White House issued a presidential proclamation on April 6, 2026, imposing 100% additional Section 232 national security tariffs on patented pharmaceuticals, active pharmaceutical ingredients, and key starting materials. The tariffs affect pharmaceutical manufacturers and U.S. importers, with phased implementation beginning July 31, 2026 for certain companies and September 29, 2026 for others. Generic pharmaceuticals and U.S.-origin products are excluded from these tariffs.
HRSA 340B Rebate Model RFI Comments Due April 20; Eli Lilly and Novo Nordisk Restrict 340B Pricing
HRSA has extended the deadline for comments on its proposed 340B rebate model pilot program to April 20, 2026. Eli Lilly and Novo Nordisk have implemented policies requiring covered entities to submit dispensing data for all 340B drugs within 45 days of dispense. These changes increase administrative burden and create risk of pricing denials and cash flow disruption for covered entities.
EPA Releases Draft Sixth Contaminant Candidate List Including Microplastics for Public Comment
The EPA and HHS released a draft Sixth Contaminant Candidate List (CCL 6) on April 2, 2026, adding microplastics among other contaminants for public comment through June 5th. The listing is required under the Safe Drinking Water Act every five years but imposes no regulatory requirements. If microplastics are later included in the Unregulated Contaminant Monitoring Rule 6, public water systems would need to sample and report during 2027-2031. California already requires statewide microplastics monitoring under SB 1422.
Halozyme US12600959B2 - Modified PH20 Hyaluronidase Polypeptides
USPTO granted Patent US12600959B2 to Halozyme, Inc. covering modified PH20 hyaluronidase polypeptides with enhanced stability and activity. The patent includes 15 claims spanning formulations, compositions, and uses thereof. Filing date was March 5, 2025, with application number 19071345.
Benzazepine derivative for vasopressin receptor disease treatment
Benzazepine derivative for vasopressin receptor disease treatment
Isoxazolo[5,4-H]quinazoline CDK Inhibitor Patent
USPTO granted patent US12600731B2 to Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. for isoxazolo[5,4-H]quinazoline compounds effective as cyclin-dependent kinase (CDK) inhibitors for treating cell proliferation disorders. The patent contains 23 claims and covers pharmaceutical compositions and methods of treating CDK-mediated diseases.
Rare Disease Advisory Council Meeting, Indianapolis, April 17th
The Indiana Department of Health announced a public meeting of the Rare Disease Advisory Council scheduled for Friday, April 17, 2026. The meeting will take place in the Yoho Executive Board Room at 2 N. Meridian St., Indianapolis, IN 46204, with livestream access available. The advisory council includes members appointed by the Governor representing physicians, nurses, pharmacists, pharmaceutical representatives, advocacy organizations, research institutes, and ex-officio members from Indiana Medicaid and the DOI Commissioner.
Certified Health Care Professions Commission Public Meeting Notice
The Indiana Department of Health has published a notice of a public meeting of the Certified Health Care Professions Commission scheduled for April 21, 2026, from noon to 3 p.m. at the Indiana Government Center South, Conference Room C in Indianapolis. The meeting will be livestreamed and is open to the public. Commission members include representatives from nurse aide, registered nurse, health facility administrator, and consumer categories.
CILAG Surgical Tissue Detection Patent (US12599379B2)
USPTO granted patent US12599379B2 to CILAG GMBH INTERNATIONAL on April 14, 2026. The patent covers devices, systems, and methods for detecting tissue and foreign objects during surgical operations using electrodes and impedance-based detection. The patent application was filed on February 26, 2024.
US12599381B2 - Surgical Stapler with Removable Power Pack
USPTO granted patent US12599381B2 to RevMedica, Inc. covering a surgical stapler with a removable power pack. The power pack contains motors and engagement members for firing fasteners and articulating the device, with sensors to track firing and articulation positions during surgery. The patent includes 19 claims.
Staple Cartridge Comprising Formation Support Features - US12599382B2
The USPTO granted Patent US12599382B2 to Cilag GmbH International for a staple cartridge comprising formation support features. The patent, granted on April 14, 2026, covers a cartridge body including staple formation features with 20 claims. The filing date was January 17, 2025.
Applied Medical Surgical Stapler Actuation Shaft Retention - US12599383B2
The USPTO granted patent US12599383B2 to Applied Medical Resources Corporation for a powered surgical stapler handle with a retention mechanism. The mechanism applies direction-dependent frictional force on an actuation shaft to prevent unintentional movement of drivetrain components. The retention feature includes a featherboard-like configuration with transverse ribs restricting movement in one direction while permitting movement in the opposite direction.
Handheld Electromechanical Surgical System Patent
USPTO granted Patent US12599378B2 to Covidien LP covering a handheld electromechanical surgical system. The device features an end effector with opposing jaw members, a drive beam, an adapter assembly, and a handle assembly with a power source, motor, force sensor, and motor controller for maintaining constant force during tissue approximation. The patent contains 17 claims and is classified under CPC codes A61B 90/06, A61B 17/068, A61B 17/072, and A61B 2090/064.
Cilag GmbH Surgical Stapler and Staple Cartridge Patent, US12599380B2
USPTO granted patent US12599380B2 to Cilag GmbH International for a surgical stapler and staple cartridge system. The patent covers a retaining pin assembly design and staple cavity configuration where outermost edges align with or extend beyond the pin rod axis. The patent includes 20 claims and was filed on April 5, 2023.
Revolution Ascend CT Security Vulnerability Recall
Health Canada issued a Type II medical device recall for GE Healthcare Japan Corporation's Revolution Ascend CT systems due to a potential security vulnerability in the AW server deployed via Edison Health Link (EHL) based CT smart subscription. Three lots are affected: AS10G2400087YC, AS10G2400056YC, and AS10G2400081YC, all with model/catalogue number 00840682146173. Healthcare providers using these devices should contact the manufacturer for additional information regarding the cybersecurity vulnerability.
Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization
Health Canada has issued a Type I recall for PUR GAS Cream Charger nitrous oxide products sold without Drug Identification Number (DIN) market authorization. The products, sold in multiple flavours including Blue Raspberry, Mango, and Grape, were marketed for inhalation purposes. Posh Glass Inc. of Calgary, Alberta is the affected company. Retailers are required to remove these products from the Canadian market.
Dexcom G7 iOS CGM App Type II Recall - Display Flicker Issue
Health Canada issued a Type II medical device recall for Dexcom G7 iOS CGM App versions 2.9.0 to 2.11.2 (model SW12300). The affected apps display a flicker that sequentially shows previous Estimated Glucose Values before displaying the current reading. Users are advised to contact Dexcom, Inc. for additional information. The recall was published April 14, 2026, with recall date April 9, 2026.
GE Precision Healthcare 3D Pleural Surface Ultrasound Patent US12599367B2
USPTO granted GE Precision Healthcare LLC Patent US12599367B2 for methods and systems generating 3D pleural surfaces from ultrasound imaging. The patent covers generating a 3D pleural surface viewed from inside the lung using 2D or 3D ultrasound images with virtual light source shading. The patent contains 16 claims and names five inventors.
FUJIFILM US12599368B2 Patent - Blood Vessel Aggregate Detection
USPTO granted patent US12599368B2 to FUJIFILM Corporation on April 14, 2026, covering an information processing apparatus, method, and program for detecting blood vessel aggregate regions in ultrasound images. The patent claims a blood vessel aggregate detection unit that identifies regions where three or more blood vessels are aggregated, and a highlight display unit that visually emphasizes these regions in the ultrasound image for medical diagnostic purposes.
Ultrasound Patent for Measuring Physiological Properties
The USPTO granted patent US12599369B2 to FUJIFILM SonoSite, Inc. for ultrasound methods and systems measuring physiological properties. The technology measures vessel-wall displacement and blood-flow velocity at two locations of the same vessel to determine pulse-wave velocity and blood pressure without requiring ECG data. The patent includes 20 claims and was filed on March 1, 2024.
FUJIFILM Ultrasound Diagnostic System with Transducer Verification Mode
The USPTO granted FUJIFILM Corporation Patent US12599370B2 for an ultrasound diagnostic system with a verification mode for detecting failed transducer channels. The system analyzes ultrasound image data to identify failed channels and adjusts detection criteria based on the influence on image quality. Application 18778868 was filed on July 19, 2024, and the patent contains 11 claims.
US12599371B2 - Apparatus and Separation Cell for Separating Drops of Biological Liquid from Transport Air
USPTO granted patent US12599371B2 to NISO BIOMED S.R.L. covering an apparatus with a separation cell for separating drops of biological liquid from transport air in flows from endoscopes. The separation cell features an inner chamber with upper inlet connectable to an endoscope, a bottom outlet for biological liquid connected to a suction pump and collection/analysis element, and an upper outlet for transport air connected to a vacuum source. The cell forms a V-shaped depression determining the transport air path. Patent includes 9 claims.
Biopsy Device Having Linear Motor
USPTO granted patent US12599373B2 to C.R. Bard, Inc. on April 14, 2026. The patent covers a biopsy device with a linear motor featuring dual feedback circuits that simultaneously control axial advancement and compensate for user movement. The 20-claim patent names Chad Van Liere and Aseem Singh as inventors.
Double-Bending Flexible Surgical Tool System
USPTO granted Patent US12599374B2 to Beijing Surgery Robotics Company Limited for a double-bending flexible surgical tool system. The system includes a mechanical arm with four continuum segments forming two dual continuum mechanisms, driven by a transmission unit to enable opposing bending movements. The patent contains 13 claims and covers surgical robotics technology for enhanced precision in surgical procedures.
GUNZE LIMITED Patent For Atrial Septal Defect Treatment
USPTO granted patent US12599375B2 to GUNZE LIMITED on April 14, 2026. The patent covers a medical material for treating atrial septal defect with a mesh structure made of bioabsorbable linear material and a reversible locking mechanism. Inventors are Yuuki Kato and Hinami Nakamura.
CooperSurgical Surgical Retractor with Non-Slip Blade Texture Patent
USPTO granted patent US12599376B2 to CooperSurgical, Inc. for an illuminated surgical retractor with a non-slip textured blade. The invention features a blade surface with preferential grip in the extraction direction and minimal grip in opposing directions. The patent contains 30 claims and names Jeffrey Ralph Swift, Jason Swift, Matthew Traub, and Nicholas Lauder as inventors.
Knee Tensioner-Balancer Method Patent B2
The USPTO granted Patent US12599377B2 to Dynamic Balancer Systems LLC on April 14, 2026. The patent covers a knee tensioner-balancer method using force sensors to evaluate human knee joints and generate digital geometric models. The invention tracks medial and lateral condyle contact points during knee flexion across a range of angles.
NY DOH Recognizes Black Maternal Health Week, Hosts Roundtable and Launches Social Media Campaign
The New York State Department of Health recognized Black Maternal Health Week (April 11-17) by hosting a roundtable discussion at Ancient Song Doula Services in Brooklyn with healthcare providers, community leaders, and policymakers to discuss critical issues affecting Black maternal health. The Department also launched a social media campaign, 'Healthy Mothers. Strong Communities,' to raise awareness about maternal health disparities and promote equitable health outcomes for Black mothers and birthing people across New York State.